US Patent 9,801,945: Claim Scope, Exclusivity, Litigation Risk, and Patent Landscape for Bupivacaine-Meloxicam Depots
US Patent 9,801,945 protects a pharmaceutical composition combining bupivacaine and meloxicam in an in-situ-forming depot or implant. The strongest commercial relevance is to Zynrelef, Heron Therapeutics’ extended-release bupivacaine and meloxicam product. The patent is composition-focused, but its dependent claims reach specific polyorthoester formulations, solvent systems, viscosity parameters, concentration ranges, release periods, and surgical pain uses.
The broadest practical barrier is claim 1. A competing product may face infringement exposure if it contains both active ingredients, falls within the specified bupivacaine-to-meloxicam ratio and meloxicam concentration ranges, and forms an implant or depot in situ. Claims 15 through 18 provide narrower protection for a particular low-viscosity polyorthoester formulation. Claims 20 through 28 cover administration and pain-treatment uses.
What does US Patent 9,801,945 protect?
US Patent 9,801,945 protects compositions and methods using bupivacaine with a small quantity of meloxicam in a delivery system that forms an implant or depot at the administration site. The patent was issued on October 31, 2017, and is associated with the bupivacaine-meloxicam technology commercialized as Zynrelef.[1][2]
The patent has two principal claim groups:
| Claim group |
Claims |
Protected subject matter |
| Composition claims |
1-19, 29-30 |
Bupivacaine, meloxicam, delivery systems, polyorthoesters, solvents, viscosity and release parameters |
| Method claims |
20-28 |
Analgesia, pain management, prophylaxis, surgical wounds, nerve blocks and postsurgical pain |
The claims use “comprising” language. That generally permits additional excipients, active ingredients, stabilizers, polymers and processing components unless another claim limitation is avoided.
How broad is independent composition claim 1?
Claim 1 is the principal composition claim. It requires:
- A delivery system.
- Bupivacaine.
- Meloxicam.
- A bupivacaine-to-meloxicam ratio of about 15:1 to 50:1.
- Meloxicam at about 0.005 wt% to 0.75 wt%.
- Formation of an implant or depot in situ.
The claim does not require the specific polyorthoester, dimethyl sulfoxide or triacetin system later recited in claims 8 through 18. That makes claim 1 materially broader than the formulation-specific claims.
Key claim limitations
| Limitation |
Scope and infringement significance |
| Bupivacaine |
The claim does not expressly limit the bupivacaine salt, although product composition and specification context may affect construction |
| Meloxicam |
Meloxicam must be present within the claimed concentration range |
| Ratio of 15:1 to 50:1 |
Likely assessed as a quantitative composition ratio, generally on a weight basis unless the intrinsic record specifies otherwise |
| Delivery system |
Broad functional limitation; it is not limited in claim 1 to a polymer |
| In-situ implant or depot |
Requires post-administration formation or persistence of a localized depot, rather than an ordinary immediate-release solution |
| “About” ranges |
Creates interpretive tolerance around numerical endpoints, subject to specification support and prosecution history |
A formulation containing bupivacaine and meloxicam does not automatically infringe. The product must satisfy the ratio, meloxicam concentration and in-situ depot limitations. A conventional injectable solution that does not form a depot would present a stronger non-infringement position, even if its active ingredients fall within the numerical ranges.
Which claims provide the strongest commercial protection?
Claims 1, 15, 17 and 18 are the most commercially significant composition claims.
Claim 1: broad active-ingredient and depot combination
Claim 1 captures a broad class of bupivacaine-meloxicam depot compositions. It is the principal risk claim for a follow-on product using the same active-ingredient combination but a different excipient system.
Claims 2 and 13-14: narrower concentration windows
These claims narrow the active concentrations:
- Bupivacaine: approximately 0.01 wt% to 7.5 wt% in claim 13.
- Meloxicam: approximately 0.005 wt% to 0.25 wt% in claim 14.
- Claim 2 specifies bupivacaine at approximately 0.1 wt% to 8.0 wt% and meloxicam at approximately 0.01 wt% to 0.5 wt%.
These claims may be useful against formulations designed around the broader ranges of claim 1 but still matching the narrower commercial concentration profile.
Claims 3-7: sustained-release and biodegradable systems
These claims require a sustained-release system and, in some cases, a semi-solid polymer formulation. Claims 6 and 7 focus on bioerodible or biodegradable polymers and in-situ depot formation.
These limitations narrow the claims but align them more closely with a commercial extended-release product.
Claims 8-12: polyorthoester and solvent system
Claims 8 through 12 focus on:
- A specified polyorthoester structure.
- A polar aprotic solvent.
- A triglyceride viscosity-reducing agent.
- Triacetin or tributyrin as the triglyceride.
- Dimethyl sulfoxide, N-methyl pyrrolidone or dimethyl acetamide as the polar aprotic solvent.
- Solubility of the active ingredients in the solvent system.
The structural formula for the polyorthoester is essential to claim construction. A text-only reproduction that omits the chemical drawings does not provide the full structural limitation. The issued patent and prosecution record control the scope of this claim.
Claims 15-18: formulation-specific protection
Claim 15 requires a formulation containing:
| Component |
Claimed amount |
| Polyorthoester |
40 wt% to 75 wt% |
| Dimethyl sulfoxide |
5 wt% to 12 wt% |
| Triacetin |
20 wt% to 40 wt% |
| Bupivacaine |
1 wt% to 5 wt% |
Claim 16 adds maleic acid at 0.01 wt% to 0.3 wt%. Claim 17 limits the polyorthoester molecular weight to 2,500 to 10,000 daltons. Claim 18 requires viscosity below 10,000 mPa-s at 37°C.
These claims create a narrower but technically specific barrier. They are more vulnerable to design-around strategies involving another polymer, another co-solvent, another viscosity modifier, a different molecular-weight distribution or a viscosity above the claimed threshold.
What methods of use are protected?
Claims 20 through 28 cover administering the claim 1 composition to produce analgesia or manage or prevent pain.
The method claims reach:
- Intramuscular administration.
- Subcutaneous administration.
- Perineural administration.
- Administration to a wound.
- Surgical wounds.
- Acute pain.
- Chronic pain.
- Postsurgical pain.
- Nerve blocks.
- Peripheral nerve blocks.
- Pain relief lasting approximately three to five days.
Claim 20 is the broadest method claim because it requires administration of the composition according to claim 1 to produce analgesia or pain relief. Claims 21 and 22 separately address pain management and prophylactic treatment.
For generic litigation, method claims may have reduced practical force where an ANDA applicant uses a limited label that omits patented indications or administration sites. Their impact depends on the proposed label, physician use, product instructions and evidence of induced infringement. Composition claims generally present the more direct barrier for an injectable product that necessarily contains the patented formulation.
What is the Orange Book status of US Patent 9,801,945?
US Patent 9,801,945 is associated with Zynrelef, the FDA-approved bupivacaine and meloxicam extended-release solution marketed by Heron Therapeutics.[2][3] FDA Orange Book listings identify patents submitted by the NDA holder or sponsor and provide the principal framework for ANDA patent certifications.[4]
| Regulatory item |
Publicly reported information |
| Product |
Zynrelef |
| Active ingredients |
Bupivacaine and meloxicam |
| Dosage form |
Extended-release solution for injection |
| NDA |
214369 |
| Sponsor |
Heron Therapeutics |
| FDA approval |
2021 |
| Patent relevance |
Composition and method protection for bupivacaine-meloxicam depot technology |
| Patent term |
Expected to extend into the early 2030s, subject to terminal disclaimers, patent-term adjustment and pediatric or other statutory extensions |
The precise Orange Book expiration and listing status should be determined from the current FDA Orange Book entry and the patent’s USPTO term data. Patent expiry cannot be inferred solely from the issue date because the term depends on the earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers and statutory extensions.[4][5]
When does US Patent 9,801,945 lose exclusivity?
The patent’s commercial exclusivity is expected to continue into the early 2030s. A conventional 20-year term is calculated from the earliest effective nonprovisional filing date, not from the grant date.[5]
The relevant exclusivity analysis has four separate dates:
| Event |
Business significance |
| Patent expiration |
Ends enforceable patent rights, subject to any valid extension |
| FDA regulatory exclusivity |
May delay approval of certain ANDAs independently of patent rights |
| Orange Book delisting |
May remove a patent from the ANDA certification framework |
| Settlement or litigation outcome |
May establish an earlier authorized generic or launch date |
A patent may remain enforceable after FDA regulatory exclusivity ends. Conversely, FDA approval timing may prevent immediate generic marketing even after a patent challenge succeeds.
What Paragraph IV challenges and litigation risks exist?
An ANDA applicant seeking approval before patent expiration would generally evaluate a Paragraph IV certification if it contends that the listed patent is invalid, unenforceable or not infringed.[4]
The principal challenge theories against the patent would likely include:
Non-infringement
A competing product could attempt to avoid claim 1 by:
- Omitting meloxicam.
- Using a bupivacaine-to-meloxicam ratio below 15:1 or above 50:1.
- Placing meloxicam outside the claimed concentration range.
- Using a delivery system that does not form an in-situ depot.
- Delivering the drug as an immediate-release solution.
- Avoiding the specific polymer or solvent limitations in the narrower claims.
Invalidity
Potential invalidity theories would focus on:
- Anticipation by earlier bupivacaine-meloxicam formulations.
- Obviousness based on known local anesthetic and NSAID combinations.
- Lack of written description or enablement for the breadth of claim 1.
- Indefiniteness involving “about,” “depot,” “implant” or the ratio limitation.
- Obviousness of the polyorthoester, DMSO and triacetin combination.
The strongest validity defense would depend on the full specification, cited references, prosecution amendments and examiner reasoning. The claim set suggests that the patent’s commercial value rests partly on the combination of drug ratio, low meloxicam loading and in-situ depot behavior rather than on either active ingredient alone.
How does the patent compare with competing long-acting local-anesthetic estates?
| Product or technology |
Active ingredient or platform |
Primary protection profile |
Competitive distinction |
| Zynrelef |
Bupivacaine plus meloxicam |
Combination composition, polymer depot and pain-use claims |
Dual analgesic and anti-inflammatory approach |
| Exparel |
Liposomal bupivacaine |
Liposome composition, manufacturing and administration patents |
Lipid-based extended release |
| XaraColl |
Bupivacaine collagen implant |
Collagen matrix and implant technology |
Solid biodegradable implant |
| Generic bupivacaine |
Bupivacaine alone |
Conventional product and process patents, if any |
Does not inherently practice the meloxicam combination claims |
| Local NSAID combinations |
NSAID plus anesthetic |
Product-specific and formulation-specific rights |
May avoid the patent if meloxicam and depot limitations are absent |
The 9,801,945 estate is differentiated by the combination of an amide local anesthetic and meloxicam. A competitor using liposomal bupivacaine without meloxicam generally would not meet claim 1. A collagen bupivacaine implant also would not necessarily infringe unless it contains meloxicam in the claimed ratio and concentration and forms the required depot.
What manufacturing and formulation barriers does the patent create?
The patent creates barriers in four technical areas:
- Active-ingredient ratio control. The bupivacaine-to-meloxicam ratio must remain within the claimed range across manufacturing batches.
- Low-dose meloxicam uniformity. Meloxicam concentrations as low as 0.005 wt% create content-uniformity and analytical-control issues.
- Depot formation. A follow-on product must demonstrate whether it forms an implant or depot in situ after administration.
- Polymer and solvent selection. The polyorthoester, DMSO and triacetin system may create formulation-development and scale-up constraints independent of patent infringement.
Claims 15 through 18 are particularly relevant to manufacturing because they define composition ranges, polymer molecular weight and viscosity at physiological temperature. A product outside one numerical range may still fall within claim 1, but it may avoid the narrower formulation claims.
What generic launch scenarios are most likely?
| Scenario |
Patent exposure |
Likely commercial outcome |
| Same bupivacaine-meloxicam depot formulation |
High |
Paragraph IV litigation likely |
| Same actives, different polymer |
Moderate |
Claim 1 remains the main risk |
| Same actives, no in-situ depot |
Lower |
Stronger non-infringement position |
| Bupivacaine-only extended-release product |
Low against this patent |
Competes with Zynrelef but does not use the claimed combination |
| Meloxicam outside claimed range |
Lower, subject to “about” construction |
May require clinical and regulatory reformulation |
| Different NSAID instead of meloxicam |
Low against literal claim 1 |
New clinical and regulatory program required |
| Label excluding patented uses |
Reduced method-claim risk |
Composition claims remain decisive |
The highest-risk challenger is a product that copies the active ingredients and depot concept while changing only the polymer or solvent. Such a product may avoid claims 8 through 18 but still confront claim 1.
How strong is the patent estate for Zynrelef?
US Patent 9,801,945 is strongest as a foundational composition patent. Its broadest claim reaches beyond the preferred polyorthoester formulation and can cover alternative delivery systems if they form an in-situ depot and satisfy the active-ingredient limitations.
Its main vulnerabilities are technical claim construction and prior-art separation. The “about” ranges, ratio limitation and in-situ depot requirement may create litigation fact issues. The narrower claims are easier to test analytically but offer more design-around opportunities.
The overall Zynrelef patent position must be assessed across the full Orange Book listing, continuation and divisional families, formulation patents, method patents and any approved-product extensions. Patent 9,801,945 alone should not be treated as the entire exclusivity estate.
What is the revenue exposure from early generic entry?
Zynrelef revenue exposure is concentrated in the premium extended-release local-anesthetic market. Early generic entry could affect:
- Hospital and ambulatory-surgery-center pricing.
- Conversion from conventional bupivacaine.
- Use in orthopedic, abdominal and pelvic procedures.
- Heron’s market access strategy.
- Licensing value for the formulation platform.
The commercial risk is highest if a generic matches the dual-active formulation and receives a broad label. A bupivacaine-only competitor would compete with Zynrelef clinically but would not replicate the meloxicam combination protected by claim 1.
Key Takeaways
- US Patent 9,801,945 protects bupivacaine-meloxicam compositions that form an in-situ implant or depot.
- Claim 1 is the central broad composition claim.
- The claimed bupivacaine-to-meloxicam ratio is approximately 15:1 to 50:1.
- Meloxicam must be present at approximately 0.005 wt% to 0.75 wt% under claim 1.
- Claims 8 through 18 narrow protection to polyorthoester, solvent, triacetin, molecular-weight and viscosity parameters.
- Claims 20 through 28 cover analgesia, postsurgical pain, wound administration and nerve blocks.
- Zynrelef is the principal commercial product associated with the patent.
- A same-active-ingredient depot product presents the highest Paragraph IV risk.
- Changing only the polymer or vehicle may avoid narrower claims but may not avoid claim 1.
- The patent is expected to provide protection into the early 2030s, subject to the official USPTO and Orange Book term records.
- The full commercial exclusivity analysis requires review of the complete Zynrelef patent family and all current Orange Book listings.
FAQs About US Patent 9,801,945
Does US Patent 9,801,945 cover bupivacaine by itself?
No. The principal composition claims require both bupivacaine and meloxicam, together with the specified ratio, concentration and in-situ depot limitations.
Does a liposomal bupivacaine product infringe this patent?
Not necessarily. A liposomal bupivacaine product without meloxicam would not satisfy the express active-ingredient requirements of claim 1.
Can a generic avoid the patent by replacing meloxicam with another NSAID?
A product using another NSAID would generally avoid literal infringement of the meloxicam limitation, although the doctrine of equivalents and other patents would require separate analysis.
Are the method claims important for an ANDA challenge?
Yes, but composition claims are usually more important where the proposed generic necessarily contains the patented combination. Method-claim exposure depends on the ANDA label and the applicant’s intended uses.
Does patent expiration immediately permit generic sale?
No. Generic launch also depends on FDA approval timing, applicable regulatory exclusivity, patent litigation outcomes, settlement terms and any other unexpired Orange Book-listed patents.
References
- United States Patent and Trademark Office. (2017). US Patent No. 9,801,945: Bupivacaine and meloxicam compositions and methods of use thereof.
- Heron Therapeutics, Inc. (2021). Zynrelef (bupivacaine and meloxicam) extended-release solution: Prescribing information.
- U.S. Food and Drug Administration. (2021). FDA approves new treatment for postoperative pain.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
- United States Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation guidance.
